S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL

S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL

Bibliographic Details
Main Authors:	Nikola Čuřík, Adam Laznicka, Vaclava Polivkova, Jitka Křížková, Pavel Semerak, Eva Pokorna, Pavla Suchankova, Pavel Burda, Andreas Hochhaus, Kateřina Machová Poláková
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967520.71557.f0

Similar Items

Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining
by: Nikola Curik, et al.
Published: (2021-09-01)

P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
by: A. Innes, et al.
Published: (2022-06-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos
by: Huan-Chau Lin, et al.
Published: (2022-10-01)

S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS
by: A. Laznicka, et al.
Published: (2022-06-01)

Expression patterns of microRNAs associated with CML phases and their disease related targets
by: Trněný Marek, et al.
Published: (2011-04-01)

Nicotinamide–Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds
by: Elizabeth Larocque, et al.
Published: (2020-02-01)

P673: ASCIMINIB MANAGMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION.
by: Elena Kuzmina, et al.
Published: (2023-08-01)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
by: Monika Jaruskova, et al.
Published: (2017-04-01)

P712: ASCIMINIB ITALIAN MANAGED ACCESS PROGRAM: EFFICACY PROFILE IN HEAVILY PRE-TREATED CML PATIENTS
by: M. Breccia, et al.
Published: (2022-06-01)

P709: CLINICAL OUTCOME OF ASCIMINIB TREATMENT IN A REAL-WORLD MULTI-RESISTANT CML PATIENT POPULATION.
by: C. C. Kockerols, et al.
Published: (2022-06-01)

P715: MULTICENTER OBSERVATIONAL STUDY OF PONATINIB IN CML PATIENTS IN ARGENTINA. REAL-WORLD EXPERIENCE.
by: M. J. Mela Osorio, et al.
Published: (2022-06-01)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: T. Hughes, et al.
Published: (2022-06-01)

P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS
by: J. Apperley, et al.
Published: (2022-06-01)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
by: Junichiro Yuda, et al.
Published: (2023-02-01)

P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
by: Timothy Hughes, et al.
Published: (2023-08-01)

P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
by: Massimo Breccia, et al.
Published: (2023-08-01)

P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY.
by: F. Khadadah, et al.
Published: (2022-06-01)

P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
by: Philipp Le Coutre, et al.
Published: (2023-08-01)

P704: ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL
by: T. Hughes, et al.
Published: (2022-06-01)

P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
by: Massimo Breccia, et al.
Published: (2023-08-01)

Ponatinib‐induced ichthyosiform eruption
by: Nicolas Kluger, et al.
Published: (2021-08-01)

Ponatinib-induced symmetric dermatitis
by: Naman Lohani, et al.
Published: (2022-01-01)

Ponatinib: A drug review
by: Hasmukh Jain, et al.
Published: (2019-01-01)

Ponatinib: Harnessing the elixir potential
by: Vishal Jayakar
Published: (2020-01-01)

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
by: Thomas Ernst, et al.
Published: (2023-08-01)

P718: ASCIMINIB MANAGED-ACCESS PROGRAM (MAP) IN RUSSIA
by: O. Shukhov, et al.
Published: (2022-06-01)

Cdx1 and Cdx2 exhibit transcriptional specificity in the intestine.
by: Stephanie Grainger, et al.
Published: (2013-01-01)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
by: N. Hijiya, et al.
Published: (2022-06-01)

P397: IKZF1 ALTERATIONS HAVE A NEGATIVE IMPACT ON EARLY MOLECULAR RESPONSE AND SURVIVAL OF ADULT PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH GMALL 07/2003 PROTOCOL IN CZECHIA
by: Vaclava Polivkova, et al.
Published: (2023-08-01)

Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts
by: Samuel J. Holzmayer, et al.
Published: (2024-03-01)

Asciminib Mitigates DNA Damage Stress Signaling Induced by Cyclophosphamide in the Ovary
by: Luca Mattiello, et al.
Published: (2021-01-01)

Nuclear orientation of152,154Tb in gadolinium
by: Ferencei, J, et al.
Published: (1981)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
by: Lukas Semerad, et al.
Published: (2023-08-01)

Ponatinib in chronic myeloid leukemia: Finally getting it right?
by: Bhausaheb Bagal, et al.
Published: (2020-01-01)

Ponatinib-associated panniculitis: Case report and review of the literature
by: Daniel Antwi-Amoabeng, et al.
Published: (2021-01-01)

GenCDX / [cakera padat]
by: 397147 Klug, William S., et al.
Published: (2000)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
by: Marianne G. Pouwer, et al.
Published: (2018-06-01)

Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells
by: Philipp Ernst, et al.
Published: (2020-09-01)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
by: Andreas Hochhaus, et al.
Published: (2023-08-01)